Overall hemostatic potential

The overall hemostatic potential (OHP) test is a global coagulation assay which can be used to measure coagulation.[1][2][3][4] The OHP assay measures total fibrin generation in the presence of thrombin or tissue factor and tissue plasminogen activator (t-PA).[2][1][3][4] It generates a fibrin time curve through the use of optical density measurement.[1] This curve represents the balance between fibrin formation induced by thrombin or tissue factor and fibrinolysis induced by t-PA.[1] The assay provides three parameters: overall coagulation potential (OCP), overall hemostatic potential (OHP), and overall fibrinolytic potential (OFP).[2][1][4] OHP is the main parameter, while OCP and OFP are supplementary parameters to assess coagulation and fibrinolysis.[3] One further parameter, clot lysis time (CLT), can also be determined.[3] The OHP assay measures the integrated effect of procoagulant, anticoagulant, and fibrinolytic factors.[1]

Overall hemostatic potential
SynonymsOverall hemostasis potential; Overall haemostasis potential; Overall haemostatic potential; OHP
Test ofCoagulation, hypercoagulability, hypocoagulability, hemostasis, fibrinolysis

The OHP is a technically simple[1][3] but relatively labor-intensive assay.[2] As of 2010, it had been implemented in several laboratories, but was not available commercially.[3] The assay is novel in terms of its combined evaluation of both fibrin generation and fibrinolysis.[1] The test is potentially useful in the evaluation of hypercoagulability, hypocoagulability, and fibrinolytic abnormalities.[1][2][3] It is able to detect hypercoagulability associated with pregnancy and estrogen/progestogen hormone therapy.[3][4] The test has also been used to study coagulation in feminizing hormone therapy in transgender women.[5] However, more studies are needed to validate the test as a biomarker of thrombosis and other abnormalities of coagulation.[2][3][4]

The original OHP assay was developed in Sweden by Blombäck and colleagues and was first described in 1999.[1][6][7] It used thrombin to trigger coagulation.[1] Since then, a modified version has been developed which can use either thrombin or tissue factor to trigger coagulation.[1][3][8][9]

References
  1. Curnow J (2017). "The Overall Hemostatic Potential (OHP) Assay". Methods Mol Biol. 1646: 523–531. doi:10.1007/978-1-4939-7196-1_38. PMID 28804852.
  2. Lim HY, Donnan G, Nandurkar H, Ho P (January 2022). "Global coagulation assays in hypercoagulable states". J Thromb Thrombolysis. doi:10.1007/s11239-021-02621-1. PMID 34997471.
  3. Antovic A (October 2010). "The overall hemostasis potential: a laboratory tool for the investigation of global hemostasis". Semin Thromb Hemost. 36 (7): 772–9. doi:10.1055/s-0030-1265294. PMID 20978998.
  4. Antovic A (July 2008). "Screening haemostasis--looking for global assays: the Overall Haemostasis Potential (OHP) method--a possible tool for laboratory investigation of global haemostasis in both hypo- and hypercoagulable conditions". Curr Vasc Pharmacol. 6 (3): 173–85. doi:10.2174/157016108784912028. PMID 18673157.
  5. Lim HY, Leemaqz SY, Torkamani N, Grossmann M, Zajac JD, Nandurkar H, Ho P, Cheung AS (July 2020). "Global Coagulation Assays in Transgender Women on Oral and Transdermal Estradiol Therapy". J Clin Endocrinol Metab. 105 (7). doi:10.1210/clinem/dgaa262. PMID 32413907.
  6. He S, Bremme K, Blombäck M (October 1999). "A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results". Thromb Res. 96 (2): 145–56. doi:10.1016/s0049-3848(99)00092-4. PMID 10574592.
  7. He S, Antovic A, Blombäck M (September 2001). "A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work". Thromb Res. 103 (5): 355–61. doi:10.1016/s0049-3848(01)00332-2. PMID 11553368.
  8. Curnow JL, Morel-Kopp MC, Roddie C, Aboud M, Ward CM (March 2007). "Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay". J Thromb Haemost. 5 (3): 528–34. doi:10.1111/j.1538-7836.2007.02362.x. PMID 17166248.
  9. Curnow, J. L. (2010). Evaluation of the overall haemostatic potential assay for the diagnosis and management of hypercoagulable states (Doctoral dissertation, University of Sydney). https://scholar.google.com/scholar?cluster=17586055299192023070


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.